176 related articles for article (PubMed ID: 8151319)
1. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J
J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319
[TBL] [Abstract][Full Text] [Related]
2. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.
Powles R; Raje N; Cunningham D; Malpas J; Milan S; Horton C; Mehta J; Singhal S; Viner C; Treleaven J
Stem Cells; 1995 Aug; 13 Suppl 2():114-7. PubMed ID: 8520498
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan for multiple myeloma: long-term follow-up data.
Cunningham D; Paz-Ares L; Gore ME; Malpas J; Hickish T; Nicolson M; Meldrum M; Viner C; Milan S; Selby PJ
J Clin Oncol; 1994 Apr; 12(4):764-8. PubMed ID: 8151320
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
[TBL] [Abstract][Full Text] [Related]
7. Double-intensive therapy in high-risk multiple myeloma.
Harousseau JL; Milpied N; Laporte JP; Collombat P; Facon T; Tigaud JD; Casassus P; Guilhot F; Ifrah N; Gandhour C
Blood; 1992 Jun; 79(11):2827-33. PubMed ID: 1350228
[TBL] [Abstract][Full Text] [Related]
8. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
9. [First-line treatment of severe myelomas of the young subject by high-dose melphalan].
Harousseau JL; Milpied N; Guilhot F; Garand R; Bourhis JH
Presse Med; 1988 Aug 27-Sep 3; 17(29):1471-4. PubMed ID: 2971190
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
12. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
13. High-dose busulfan in patients with myeloma.
Mansi J; da Costa F; Viner C; Judson I; Gore M; Cunningham D
J Clin Oncol; 1992 Oct; 10(10):1569-73. PubMed ID: 1403036
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation.
Hartmann O; Kalifa C; Benhamou E; Patte C; Flamant F; Jullien C; Beaujean F; Lemerle J
Cancer Chemother Pharmacol; 1986; 16(2):165-9. PubMed ID: 3512113
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma treated with high dose intravenous melphalan.
Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
[TBL] [Abstract][Full Text] [Related]
16. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group.
Bonetti F; Zecca M; Pession A; Messina C; Montagna D; Lanino E; Fagioli F; Santoro N; Prete A; Cesaro S; Rondelli R; Giorgiani G; De Stefano P; Locatelli F
J Clin Oncol; 1999 Dec; 17(12):3729-35. PubMed ID: 10577844
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Attal M; Harousseau JL; Stoppa AM; Sotto JJ; Fuzibet JG; Rossi JF; Casassus P; Maisonneuve H; Facon T; Ifrah N; Payen C; Bataille R
N Engl J Med; 1996 Jul; 335(2):91-7. PubMed ID: 8649495
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
19. Intensive treatment of multiple myeloma and criteria for complete remission.
Gore ME; Selby PJ; Viner C; Clark PI; Meldrum M; Millar B; Bell J; Maitland JA; Milan S; Judson IR
Lancet; 1989 Oct; 2(8668):879-82. PubMed ID: 2571812
[TBL] [Abstract][Full Text] [Related]
20. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
